Latest From Singulex Inc.
Inivata's Chief Medical Officer Clive Morris will take over as CEO of the liquid biopsy company. Former CEO Michael Stocum departed earlier this year.
Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.
Results of from a new analysis of plasma samples from an old statin trial suggest that Singulex’ high-sensitivity cardiac troponin test can track the cardiovascular risk in stable patients with ischemic heart disease.
Singulex originally developed its Single Molecule Counting technology for research applications, but it is poised to launch a clinical diagnostics tool that incorporates the highly sensitive technology.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Singulex Inc.
- Senior Management
Guido Baechler, Pres. & CEO
Eric Hall, CFO
Bob Brousseau, VP, Sales & Mktg.
Jeffrey Bishop, PhD, VP, R&D
Linda M Greub, VP, Bus. Dev.
- Contact Info
Phone: (510) 995-9000
1701 Harbor Bay Pkwy.
Alameda, CA 94502
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.